Abstract
Background: Malignant tumor is still one of the important diseases worldwide, cytotoxic CD8+ T lymphocytes (CTLs) play an important role in killing tumor cells.
Objective: To enhance the immune response of our previously identified HLA-A2-restricted CTL epitopes, we designed a multiepitope YL66. Method: The fusion protein GST-YL66 and DNA vaccine pcDNA3.1(+)-YL66 were used to induce CTLs from human peripheral blood mononuclear cells (PBMCs) of HLA-A*02+ healthy donors and and in HLA-A2.1/Kb transgenic(Tg) mice. and the activity of induced CTLs were tested by IFN-γ relesde ELISPOT assay and LDH cytotoxicity assay. Results: GST-YL66 induced CTL could lysis tumor cells and release IFN-γ both in vitro and in vivo, and pcDNA3.1(+)-YL66 could also induce significant CTL response in vivo. Conclusion: The designed fusion multiepitope YL66 could be used as a vaccine against patients with tumors expressing COX-2 and/or MAGE-4.Keywords: Cytotoxic T lymphocytes, vaccine, cancer immunotherapy, HLA-A2, epitope, YL66.
Graphical Abstract
Protein & Peptide Letters
Title:A Novel Recombinant Multi-Epitope Vaccine Could Induce Specific Cytotoxic T Lymphocyte Response In Vitro and In Vivo
Volume: 24 Issue: 6
Author(s): Yahong Wu, Wenjie Zhai, Meng Sun, Zhe Zou, Xiuman Zhou, Guodong Li, Zhongyi Yan, Yuanming Qi*Yanfeng Gao*
Affiliation:
- School of Life Sciences, Zhengzhou University, 100 Kexue Road, Zhengzhou 450001,China
- School of Life Sciences, Zhengzhou University, 100 Kexue Road, Zhengzhou 450001,China
Keywords: Cytotoxic T lymphocytes, vaccine, cancer immunotherapy, HLA-A2, epitope, YL66.
Abstract: Background: Malignant tumor is still one of the important diseases worldwide, cytotoxic CD8+ T lymphocytes (CTLs) play an important role in killing tumor cells.
Objective: To enhance the immune response of our previously identified HLA-A2-restricted CTL epitopes, we designed a multiepitope YL66. Method: The fusion protein GST-YL66 and DNA vaccine pcDNA3.1(+)-YL66 were used to induce CTLs from human peripheral blood mononuclear cells (PBMCs) of HLA-A*02+ healthy donors and and in HLA-A2.1/Kb transgenic(Tg) mice. and the activity of induced CTLs were tested by IFN-γ relesde ELISPOT assay and LDH cytotoxicity assay. Results: GST-YL66 induced CTL could lysis tumor cells and release IFN-γ both in vitro and in vivo, and pcDNA3.1(+)-YL66 could also induce significant CTL response in vivo. Conclusion: The designed fusion multiepitope YL66 could be used as a vaccine against patients with tumors expressing COX-2 and/or MAGE-4.Export Options
About this article
Cite this article as:
Wu Yahong, Zhai Wenjie , Sun Meng , Zou Zhe, Zhou Xiuman , Li Guodong, Yan Zhongyi , Qi Yuanming *, Gao Yanfeng *, A Novel Recombinant Multi-Epitope Vaccine Could Induce Specific Cytotoxic T Lymphocyte Response In Vitro and In Vivo, Protein & Peptide Letters 2017; 24 (6) . https://dx.doi.org/10.2174/0929866524666170419152700
DOI https://dx.doi.org/10.2174/0929866524666170419152700 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting Inhibitor of Apoptosis Proteins (IAPs) for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Emerging Therapeutic Targets in Regenerative Medicine for the Treatment of Diabetes Mellitus: A Patent Literature Review
Recent Patents on Regenerative Medicine Meet Our Associate Editorial Board Member
Current Pharmaceutical Biotechnology Nitric Oxide and the Regulation of Apoptosis in Tumour Cells
Current Pharmaceutical Design Tumor Dormancy and the Angiogenic Switch: Possible Implications of Bone Marrow- Derived Cells
Current Pharmaceutical Design Antimicrobial Potential of Benzamides and Derived Nanosystems for Controlling in vitro Biofilm Development on Medical Devices
Current Organic Chemistry Prevention of Microbial Communities: Novel Approaches Based Natural Products
Current Pharmaceutical Biotechnology Histamine and Histaminergic Receptors in Colorectal Cancer: From Basic Science to Evidence-based Medicine
Anti-Cancer Agents in Medicinal Chemistry OMICS-Derived Targets for Inflammatory Gut Disorders: Opportunities for the Development of Nutrition Related Biomarkers
Endocrine, Metabolic & Immune Disorders - Drug Targets Bone Morphogenetic Protein-Smad Pathway as Drug Targets for Osteoporosis and Cancer Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Gold(III) Complexes in the Oncological Preclinical Arena: From Aminoderivatives to Peptidomimetics
Current Topics in Medicinal Chemistry Synthesis and Antitumoral Evaluation of 7-chloro-4-quinolinylhydrazones Derivatives
Medicinal Chemistry The Adipose Tissue as a Source of Vasoactive Factors
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Current Molecularly Targeting Therapies in NSCLC and Melanoma
Anti-Cancer Agents in Medicinal Chemistry Application of Baculovirus-Insect Cell Expression System for Human Therapy
Current Pharmaceutical Biotechnology Cyclodextrin-based Polymeric Nanoparticles as Efficient Carriers for Anticancer Drugs
Current Pharmaceutical Biotechnology The Yin and Yang of the Ghrelin Gene Products
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Potassium Channels: Novel Emerging Biomarkers and Targets for Therapy in Cancer
Recent Patents on Anti-Cancer Drug Discovery Cytochrome P450 Drug Metabolizing Enzymes in Roma Population Samples: Systematic Review of the Literature
Current Medicinal Chemistry [General Articles] Intracellular Thiol Concentration Modulating Inflammatory Response: Influence on the Regulation of Cell Functions Through Cysteine Prodrug Approach
Current Medicinal Chemistry